Trade Delcath Systems, Inc. - DCTH CFD

Add to favourite

4.76

1.07%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.04

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	4.67
Open*	4.71
1-Year Change*	-13.58%
Day's Range*	4.57 - 4.72
52 wk Range	2.25-7.99
Average Volume (10 days)	325.97K
Average Volume (3 months)	7.65M
Market Cap	84.66M
P/E Ratio	-100.00K
Shares Outstanding	22.05M
Revenue	2.17M
EPS	-3.52
Dividend (Yield %)	N/A
Beta	0.52
Next Earnings Date	Mar 25, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	4.67	0.31	7.11%	4.36	4.98	4.24
Apr 17, 2024	4.45	-0.19	-4.09%	4.64	4.74	4.42
Apr 16, 2024	4.70	-0.05	-1.05%	4.75	4.82	4.63
Apr 15, 2024	4.82	-0.04	-0.82%	4.86	4.97	4.69
Apr 12, 2024	4.93	-0.02	-0.40%	4.95	4.97	4.81
Apr 11, 2024	4.98	0.05	1.01%	4.93	5.05	4.88
Apr 10, 2024	4.97	0.08	1.64%	4.89	5.00	4.83
Apr 9, 2024	4.96	-0.03	-0.60%	4.99	5.04	4.87
Apr 8, 2024	5.01	0.07	1.42%	4.94	5.31	4.94
Apr 5, 2024	4.97	0.12	2.47%	4.85	5.08	4.85
Apr 4, 2024	5.00	0.17	3.52%	4.83	5.07	4.83
Apr 3, 2024	4.83	0.19	4.09%	4.64	4.88	4.64
Apr 2, 2024	4.67	-0.11	-2.30%	4.78	4.79	4.59
Apr 1, 2024	4.77	0.02	0.42%	4.75	4.99	4.74
Mar 28, 2024	4.76	-0.24	-4.80%	5.00	5.00	4.74
Mar 27, 2024	5.06	0.37	7.89%	4.69	5.13	4.52
Mar 26, 2024	4.59	0.04	0.88%	4.55	4.72	4.30
Mar 25, 2024	4.62	-0.01	-0.22%	4.63	4.85	4.53
Mar 22, 2024	4.67	0.01	0.21%	4.66	4.70	4.40
Mar 21, 2024	4.66	0.23	5.19%	4.43	4.73	4.30

Delcath Systems, Inc. Events

Time (UTC)	Country	Event
Friday, May 10, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Delcath Systems Inc Earnings Release Q1 2024 Delcath Systems Inc Earnings Release Forecast - Previous -
Tuesday, June 11, 2024
Time (UTC) 14:00	Country US	Event Delcath Systems Inc Annual Shareholders Meeting Delcath Systems Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, August 7, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Delcath Systems Inc Earnings Release Q2 2024 Delcath Systems Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	2.719	3.555	1.646	1.58	3.407
Revenue	2.719	3.555	1.646	1.58	3.407
Cost of Revenue, Total	0.686	0.671	0.64	0.719	1.009
Gross Profit	2.033	2.884	1.006	0.861	2.398
Total Operating Expense	36.572	28.086	22.949	21.488	31.601
Selling/General/Admin. Expenses, Total	16.103	13.637	11.108	11.279	9.819
Research & Development	18.583	13.778	11.201	9.49	19.65
Operating Income	-33.853	-24.531	-21.303	-19.908	-28.194
Interest Income (Expense), Net Non-Operating	-2.685	-1.186	-3.007	11.027	8.921
Other, Net	0.03	0.068	0.154	0.002	0.051
Net Income Before Taxes	-36.508	-25.649	-24.156	-8.879	-19.222
Net Income After Taxes	-36.508	-25.649	-24.156	-8.879	-19.222
Net Income Before Extra. Items	-36.508	-25.649	-24.156	-8.879	-19.222
Net Income	-36.508	-25.649	-24.156	-8.879	-19.222
Total Adjustments to Net Income		0	-0.055		0
Income Available to Common Excl. Extra. Items	-36.508	-25.649	-24.211	-8.879	-19.222
Income Available to Common Incl. Extra. Items	-36.508	-25.649	-24.211	-8.879	-19.222
Diluted Net Income	-36.508	-25.649	-24.211	-8.879	-19.222
Diluted Weighted Average Shares	8.86462	7.14575	2.89783	0.0259	0.03819
Diluted EPS Excluding Extraordinary Items	-4.1184	-3.5894	-8.35488	-342.819	-503.343
Diluted Normalized EPS	-3.98303	-3.5894	-8.35488	-342.819	-473.936
Unusual Expense (Income)	1.2			0	1.123
Total Extraordinary Items

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0.495	0.597	0.639	0.906	0.797
Revenue	0.495	0.597	0.639	0.906	0.797
Cost of Revenue, Total	0.15	0.181	0.237	0.235	0.18
Gross Profit	0.345	0.416	0.402	0.671	0.617
Total Operating Expense	8.492	8.922	10.165	8.707	10.283
Selling/General/Admin. Expenses, Total	4.787	4.165	4.994	3.319	4.497
Research & Development	3.555	4.576	4.934	3.953	5.606
Operating Income	-7.997	-8.325	-9.526	-7.801	-9.486
Interest Income (Expense), Net Non-Operating	0.789	-0.688	-0.645	-0.73	-0.665
Other, Net	0.006	0.013	0.028	0.026	-0.008
Net Income Before Taxes	-7.202	-9	-10.143	-8.505	-10.159
Net Income After Taxes	-7.202	-9	-10.143	-8.505	-10.159
Net Income Before Extra. Items	-7.202	-9	-10.143	-8.505	-10.159
Net Income	-7.202	-9	-10.143	-8.505	-10.159
Income Available to Common Excl. Extra. Items	-7.202	-9	-10.143	-8.505	-10.159
Income Available to Common Incl. Extra. Items	-7.202	-9	-10.143	-8.505	-10.159
Diluted Net Income	-7.202	-9	-10.143	-8.505	-10.159
Diluted Weighted Average Shares	12.4637	11.6224	9.85044	9.21579	8.19048
Diluted EPS Excluding Extraordinary Items	-0.57784	-0.77437	-1.0297	-0.92287	-1.24034
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.57784	-0.77437	-1.0297	-0.79266	-1.24034
Total Adjustments to Net Income
Unusual Expense (Income)			0	1.2

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	16.155	31.152	32.338	12.617	5.919
Cash and Short Term Investments	7.671	22.802	28.575	10.002	2.516
Cash & Equivalents	7.671	22.802	28.575	10.002	2.516
Total Receivables, Net	0.366	0.044	0.057	0.021	1.164
Accounts Receivable - Trade, Net	0.366	0.044	0.057	0.021	0.585
Total Inventory	1.998	1.412	0.855	0.654	0.858
Other Current Assets, Total	4.369	5.264	0.181	0.181	1.381
Total Assets	17.862	33.124	34.635	14.212	6.844
Property/Plant/Equipment, Total - Net	1.707	1.972	2.297	1.595	0.925
Property/Plant/Equipment, Total - Gross	6.638	6.797			5.232
Accumulated Depreciation, Total	-4.931	-4.825			-4.307
Total Current Liabilities	14.735	5.954	10.035	15.994	17.75
Accounts Payable	2.018	0.638	1.774	4.533	7.715
Accrued Expenses	4.871	3.974	5.736	7.611	3.434
Notes Payable/Short Term Debt	0	0.551	0	0	0
Current Port. of LT Debt/Capital Leases	7.846	0.621	2	0	2.038
Other Current Liabilities, Total	0	0.17	0.525	3.85	4.563
Total Liabilities	23.721	21.172	12.557	20.569	21.783
Total Long Term Debt	7.842	15.011	0	2	0
Other Liabilities, Total	1.144	0.207	2.522	2.575	4.033
Total Equity	-5.859	11.952	22.078	-6.357	-14.939
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.1	0.079	0.06	0.001	0.103
Additional Paid-In Capital	451.608	432.831	417.449	364.785	328.962
Retained Earnings (Accumulated Deficit)	-457.484	-420.976	-395.327	-371.171	-344.054
Treasury Stock - Common					0
Other Equity, Total	-0.083	0.018	-0.104	0.028	0.05
Total Liabilities & Shareholders’ Equity	17.862	33.124	34.635	14.212	6.844
Total Common Shares Outstanding	10.0466	7.90673	5.9961	0.06709	0.01463
Prepaid Expenses	1.751	1.63	2.67	1.759
Other Long Term Assets, Total				0
Long Term Debt	7.842	15.011	0	2
Total Preferred Shares Outstanding	0.01136	0.01136

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	46.096	19.472	29.022	16.155	18.48
Cash and Short Term Investments	40.462	14.54	24.222	7.671	9.831
Cash & Equivalents	40.462	14.54	24.222	7.671	9.831
Total Receivables, Net	0.205	0.127	0.458	0.366	0.537
Accounts Receivable - Trade, Net	0.205	0.127	0.458	0.366	0.537
Total Inventory	2.667	2.48	2.337	1.998	1.926
Prepaid Expenses	2.285	2.019	1.721	1.751	1.84
Other Current Assets, Total	0.477	0.306	0.284	4.369	4.346
Total Assets	47.577	21.05	30.599	17.862	20.226
Property/Plant/Equipment, Total - Net	1.481	1.578	1.577	1.707	1.746
Property/Plant/Equipment, Total - Gross	6.498	6.577	6.547	6.638	6.609
Accumulated Depreciation, Total	-5.017	-4.999	-4.97	-4.931	-4.863
Total Current Liabilities	13.974	11.114	13.411	14.735	14.446
Accounts Payable	0.753	0.966	2.428	2.018	2.632
Accrued Expenses	5.265	5.638	7.213	4.871	5.333
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	7.956	4.51	3.77	7.846	6.481
Other Current Liabilities, Total				0	0
Total Liabilities	22.858	21.292	25.307	23.721	25.472
Total Long Term Debt	2	5.252	5.798	7.842	9.727
Other Liabilities, Total	6.884	4.926	6.098	1.144	1.299
Total Equity	24.719	-0.242	5.292	-5.859	-5.246
Common Stock	0.197	0.153	0.101	0.1	0.086
Additional Paid-In Capital	518.607	473.355	453.37	451.608	442.066
Retained Earnings (Accumulated Deficit)	-494.026	-473.686	-466.483	-457.484	-447.341
Other Equity, Total	-0.059	-0.064	-0.064	-0.083	-0.057
Total Liabilities & Shareholders’ Equity	47.577	21.05	30.599	17.862	20.226
Total Common Shares Outstanding	19.689	15.2505	10.0816	10.0466	8.59768
Long Term Debt	2	5.252	5.798	7.842	9.727
Preferred Stock - Non Redeemable, Net	0	0	18.368	0	0
Total Preferred Shares Outstanding	0.03779	0.02098	0.01136	0.01136	0.01136

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-36.508	-25.649	-24.156	-8.879	-19.222
Cash From Operating Activities	-24.95	-22.604	-22.868	-23.69	-14.732
Cash From Operating Activities	0.132	0.146	0.167	0.212	0.444
Non-Cash Items	9.312	8.663	6.927	-7.92	-7.726
Changes in Working Capital	2.114	-5.764	-5.806	-7.103	11.772
Cash From Investing Activities	-0.209	-0.143	-0.782	-0.024	-0.076
Capital Expenditures	-0.209	-0.143	-0.782	-0.024	-0.076
Other Investing Cash Flow Items, Total
Cash From Financing Activities	10.143	20.822	42.355	30.305	13.236
Financing Cash Flow Items		0	-0.107	26.475	0
Issuance (Retirement) of Stock, Net	10.857	6.385	42.488	0.15	12.442
Issuance (Retirement) of Debt, Net	-0.714	14.437	-0.026	3.68	0.794
Foreign Exchange Effects	-0.115	0.122	-0.132	0.014	-0.174
Net Change in Cash	-15.131	-1.803	18.573	6.605	-1.746
Cash Interest Paid	1.873	0.681	0.011

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-9	-36.508	-26.365	-17.86	-8.203
Cash From Operating Activities	-4.264	-24.95	-17.591	-12.412	-6.375
Cash From Operating Activities	0.03	0.132	0.098	0.031	0.031
Non-Cash Items	1.982	9.312	5.378	3.785	1.805
Cash Interest Paid	0.491	1.873	1.337	0.842	0.411
Changes in Working Capital	2.724	2.114	3.298	1.632	-0.008
Cash From Investing Activities	0	-0.209	-0.209	-0.141	-0.089
Capital Expenditures	0	-0.209	-0.209	-0.141	-0.089
Cash From Financing Activities	16.694	10.143	4.896	0	0
Issuance (Retirement) of Stock, Net	23.007	10.857	4.896	0	0
Issuance (Retirement) of Debt, Net	-6.313	-0.714	0
Foreign Exchange Effects	0.02	-0.115	-0.067	-0.046	0.002
Net Change in Cash	12.45	-15.131	-12.971	-12.599	-6.462
Financing Cash Flow Items

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Delcath Systems, Inc. Company profile

About Delcath Systems Inc

Delcath Systems, Inc. is an oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company is a specialty pharmaceutical and medical device company developing its products. The Company's lead product candidate is HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Delcath Systems Inc revenues increased 27% to $1.4M. Net loss applicable to common stockholders increased 18% to $20.3M. Revenues reflect Product revenue increase of 35% to $1.1M, Other revenue increase of 9% to $392K. Higher net loss reflects Research and development expenses increase from $3M to $8.3M (expense), Stock-based Compensation in SGA increase from $49K to $4.2M (expense), Selling.

Equity composition

Common Stock $.01 Par, 12/10, 70M auth., 43,028,146 issd., less 28,100 shares in Treas. @ $51.1M. Insiders control 1.42%. InitialPublic Offering 10/20/00, 1.2M Units (1 Common+ 1Redeemable Warrant) @ $6 by Whale Securities Co . 5/20/03,Company sold 677,419 Units (5 Common + 5 Warrants) @ $3.10/unit. 98.3. 04/14, 1-for-16 Reverse stock split.

Industry:

Medical Prosthetics

1633 Broadway Ste 22C
NEW YORK
NEW YORK 10019-6708
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024